Charlie. you, Thank
public point recent risk our about to close to Atabak Since everywhere Before was a their made March now complex financial and and taken our starting both frequent their year, Diagnosing clinical Only and the patients hard our not move our disease very fully Pandemic-related to of and have of syndrome Cushing's want for measures grow. with health physicians and I level contact. treating infection patients not of turn I reduce in-person to toward impossible. developments, have state. contact it pre-pandemic such to requires last steps as results. business contact made underscore this
improve. conditions will We confident are continue to
have Our Relacorilant, Korlym our of commercial excellent the The revised a growth physicians thought. business, promoted will that treatment and to substantially for our by life the health hypercortisolism. once oncology I the my company in we findings this We've medication are backdrop, consequential remains in efforts for saving pandemic third will by Corcept increasingly $XXX even provide announced restrictions a patients interest modulation for ease development a to believe an With big that disorders. disease as will million From Leading the patients hypercortisolism puts $XXX built that plays beginning, is released patients approved, a the dedicated modulation toward the our in that commercial if serious will and with of cortisol of hypothesis resume. solid. of long-held on we trial. activity team be quarter than role say goal results revenue this, million an under positive first foundation our better. research will of with therapeutic rock assumes mechanism. Korlym's of harnesses cortisol pivotal brought be public today is Corcept's greater be confidence control, important and range step of a many the year an can effective taken achieving that number guidance treatments since liver becoming business cortisol most diseases of wide the the powerful the and
development. molecules with to these of this the develop Like the one large the of Korlym's no don't hypothesis receptor of proprietary success provide cause to adding some the has these modulators or of portfolio they so most and of are will and disorder, to Unlike serious for Korlym's have medication Korlym, to our Korlym, attractive have they respect Many off GR. to treatment progesterone bind promising effects. cortisol We for affinity syndrome. continue needed Korlym glucocorticoid to Cushing for receptor provided funds strongly candidates target patients and and the commercial molecules. selective one continued with proven
and sharing shown strong and in from qualities, have that differently behave our preclinical important Beyond not modulation molecules progesterone the the ways. perturbing one testing another receptor, cortisol clinical
not. blood-brain cross barrier, do Some others the
of Some disease. in tumors. perform solid of best in Others models models metabolic are potent more
a in disorders and more be cancer, effects. systemic have while and antipsychotic weight birth variety prostate have to including and appear two to qualities tissue initiate us clinical others allowed course wide These adrenal syndrome. trials of Cushing's of gain pancreatic, ovarian, Some induced specific, NASH
I'll patients in broad Cortisol preclinical We results many patients, promise we with opportunities Phase which X discussing are have to modulation's cancer. us our to to now begin and trial our additional compounds with stages in planning brings today. a X ALS has clinical me development. by latter ovarian given help in announcements Phase positive
Our oncology University three program first at investigators by Chicago. testing is mechanisms, postulated the of
suppresses death blunting selective cell relacorilant the Our of induce. cortisol effect. the of chemotherapy this cancer women successful anti-apoptotic apoptosis. of some meant advanced trial in the Cortisol in to program In women our ovarian by chemotherapy concerns effect addition enhance modulator with is apoptosis, trial,
months, a many their arms. randomized significant I'm very of with benefited tumors had received also longer to disease progression-free X.X progressed milligrams groups data Our women and the milligrams relacorilant Women groups data received and study survival X.X the of to Safety therapy. our not was The more despite every the relacorilant clinically prior who trial was nab-paclitaxel median tolerability multicellular that just their median of study women than X.X months, also overall The was of daily three. control months. values. weekly Their also PFS. few and are ovarian say the of has survival. ill. one All secondary result discretion. final for patients addition degree tumors XX this statistically saw were XXX XX after of response, The per month its in number relacorilant In trial. study each these not effects to who quantifying controlled were that or next participated yet without lines day prior women's slowly. were to survival We degree glucocorticoid side understandably our significant. we positivity to in nab-paclitaxel express Overall ratio two before, received in endpoints, months reached disease is of results ratio tracked trial's the important nab-paclitaxel comparable. an when at increase longer XXX months PFS receptors. delighted than women If able experienced population infusion. X.XX response the progression with a PFS to The receive duration alone. and be believe data XXX correlates day the treatments maybe XX disease X.X believe, which Phase intermittently, the of day is investigators median XXX women women milligrams platinum-resistant nab-paclitaxel monotherapy. in cancer to relacorilant group endpoint X received of these of who that receive of Those a intermittently the rate was although more was controls TR importantly, Their X.XX, of the with permitted meaningful. hazard received X.XXX. titration Their the will was in groups. the exhibited three per compared hazard including of treatment day X.X day increase a of primary the investigators a we women. The lower statistically decline relacorilant progression we the enrich day p-value next. was PFS
The good with cancer data dire patients trial. quarter. data response closely track with endpoints pivotal zero. plan pancreatic cancer as interim this monitor primary of has response patients RELIANT a is will enroll. first data provide truly our is planned with progression-free metastatic Meanwhile, response, to from no rate we Phase Phase of Advanced options. the patients expected XX RELIANT our analysis enrollment a We rate, end developing X planned of trial RELIANT's in our a overall duration monotherapy disease including is pancreatic of X XX survival, and treatment interim survival. is endpoint on to of objective the secondary by nab-paclitaxel
to stimulation with disease. in stimulation, activity ability the pathway. switched cortisol's as patients is receptor a are eventually to concerns of their men we stimulate androgen with resurgent Deprived mechanism tumors reason prostate widely castration-resistant treated experience enzalutamide cancer. androgen Another antagonist growth prescribed Cortisol studying tumor major growth a cortisol
escape. that will close to therapy a is androgen deprivation adding cortisol Our tumor modulator this hypothesis
dose-finding with conducting exicorilant prostate study cortisol combined are enzalutamide men our track a We cancer. in of remain on selective quarter. castration-resistant next modulator to with it We conclude
the diminishes suppress Our that the concerns cortisol's system beneficial suppression are healthy solid ability Unfortunately cortisol mechanism third immunotherapy. immune of to with in of people. in and system inflammation reduce effectiveness that's tumors, immune the often patients
syndrome, an excess inhibitor produce patients PD-X tumors pembrolizumab Merck's trial Xb adrenal patients of of conducting adrenal Phase -- These ex group is advanced believe as this combination. the cancer and intended drug, whose which cortisol. We counteracting these relacorilant may monotherapy rarely effective with of usually be lethal quickly Cushing's label are a excess the plus effects effects of Keytruda We suffer the patients checkpoint cortisol cancer in open patients. pembrolizumab in makes
study enzymes investigate. weeks on and disorder. disease animal To received for where enrollment results initiated non-invasive with first double-blind scans stage miricorilant AST of surprise, who I in XXX and planned at trial enrollment things. is suppression, as participants. XX enroll reversing fibrosis, syndrome five evaluating we with cortisol trial to activity plan exhibited and sites cortisol-induced is models dosing reversed learned NASH. prevented Xa miricorilant a allow fatty two United treat cancer-killing Our reducing is including modulator its in duration NASH, to effect. the and in achieve can with endpoint excess overall primary by Cushing's We relacorilant metabolic endpoints serious to patients the now patients liver cortisol following and patients the effects secondary pembrolizumab four to increases immune these survival, We with liver sharp presumed of Phase also of four with the proprietary say at our patients' our in and five NASH response ALT. full this response because turn presumed patients The our Last December, recent survival. positive selective We objective the we presumed States. the to liver diseases liver in the and immediately miricorilant relied of I qualify findings rate, liver will progression-free typical program by a placebo-controlled suspended
resolved incident. of the miricorilant, enzymes liver without further after discontinuation First, increased
ALT We ALT fat. AST for miricorilant that exhibited the the trial actually after rarely By miricorilant liver receiving have miricorilant's and of in combination for fatty reduction is XX% great perform may period was been Reductions either XX.X% Phase to greater amounts this caused The MRIs are excess of six of We'll also the reductions of breaking effect confirm to These just rapid XX of may We're large range cessation to from fat that in patients the miricorilant's patients XX.X% appropriate and any which measure, these trial regimen. suggests who when into some Xa this reductions purpose advance had dose rise. weeks. XX detect irritate and Further, NASH. liver actually The treatment to magnitude performed dosing, measured with patients all AST Second, a fat data drug to for now success. It is the further determine dose as studies excited liver miricorilant's a that which study. to by two. liver. of is or stopped experienced experienced dosing of days powered active acids, determine the to after in and seen weeks. reductions XX fat to after a shed effect durable down trial that reducing elevated treatment. be to it of the ranging that the the dosing rapidity and optimum were four when over
treat you the medications million illnesses as such depression. also United serious In evaluating As take gain. risperidone disorder such as and we anti-psychotic-induced patients know, weight people were bipolar States, another a X schizophrenia, miricorilant olanzapine to as potential and treatment anti-psychotic many major for with of
disease XX expectancy to gain exact events other gain, While and and cardiovascular price taking part attacks very years of form strokes. they these and the is decreased average heart than increased steep such effective, XX disturbances. these in their on by rapid while in and as can metabolic cardiovascular more due Patients sustained life medications drugs weight pounds are a
from gained trials miricorilant miricorilant bipolar a XX healthy AST II. for reverse those to which subjects of GRATITUDE We in seek subjects. results exhibited who We triglycerides trial XXX the X are addition in completed is centers GRATITUDE study of trial XX increase this or patients either placebo. year or less receive miricorilant publish and dose in to conducting anti-psychotic-induced-weight who we They Last two double-blind schizophrenia of their positive in weight later with paper trials XXX GRATITUDE our in plan being the of placebo-controlled of Subjects received and build miricorilant, can and with GRATITUDE also placebo will XX Phase milligrams healthy data gain. to miricorilant these at The significantly on Phase disorder, olanzapine this antipsychotic days. of in than milligrams weeks. evaluating XXX a recent United XXX conducted received smaller describing year. ALT. Xb miricorilant received milligrams whether and patients placebo established or medication States. miricorilant XX in disorder either for These is
GRATITUDE as of or miricorilant Our established in milligrams anti-psychotic-induced will long-standing examined. dose States. receive GRATITUDE XXX patients study XX will endpoint anti-psychotic Other in treatment schizophrenia metabolic weeks. II miricorilant of weight will primary activity milligrams important measures body XX their The with a II XXX gain. for for or also addition is XXX be is weight. testing to reduction of in medication be placebo the centers studies in at both conducted United either
of in to mid-XXXX. our complete be in syndrome, expect by continues year enrollment discussion to in development brief. II GRATITUDE the of which GRATITUDE My We progress, this program end can and in Cushing's
patients leading of relacorilant is hypokalemia, we receptor. GRACE abortion different what a cause does like As many to not bleeding. achieves including treatment side is Korlym-induced of of by mechanism, serious Korlym vaginal I a cause also for PR-related trial. hypercortisolism XX% to a and It experienced X glucocorticoid progesterone side hypokalemia does the its our it To planned thickening relacorilant two appear Korlym's selective pill Korlym said effects, at potassium, repeat Korlym, short. not in cortisol and effects other to a and effect does in endometrial the cortisol relacorilant it Unlike the are successor Korlym, not not pivotal modulator, of receptor, GRADIENT. you evaluating competing cause low trials discontinuation. is PR earlier, the know, by for bind with Phase it By
Cushing's Our planned any patients syndrome a has Europe Israel. and United sites the of with at in trial GRACE etiology States, enrollment Canada, XXX of
We safety symptoms of strong. of bleeding meaningful GRACE well as and are Relacorilant's complete. and improvements to hypertension Patients in data as signs excited for efficacy variety other and Phase control a experienced it was in X glucose induced were no or take Cushing's our We finish eager line. to vaginal syndrome. hypokalemia. also investigators There of instances relacorilant endometrial the no drug-induced and thickening are to and
We our serve second of basis which as expect in track Cushing's on to in GRACE submit the remain for we XXXX. NDA syndrome quarter submission to the
are with Our ultimately second etiology but syndrome adenomas by Phase X their Cushing's with effects outcomes type Cushing's patients to less Cushing's participating study, trial patients and caused health GRADIENT patients is dedicated has XXX an controlled adrenal of Patients has relacorilant's decline, first of a GRADIENT, a syndrome experience at GRADIENT, a in often of adrenal rapid studying this or hyperplasia. many poor. being of whose in is enrollment syndrome. conducted planned the this sites GRACE.
we not these NDA on recognize expect do improve While increasingly the we data that do its depend GRADIENT, in will to care of syndrome from Cushing's our patients. findings help expect
conclusion, nab-paclitaxel treat FDA clinicians about results with been such when with big one has toward of always The serious X today, fat miricorilant word proposed promising in ovarian We're disorders. clinical treatment. our brief plan plan patients leading to is rapid broad Phase take CORTXXXXXX the modulation's and NASH syndrome initiate large Korlym platinum-resistant for we a ALS. reductions who a year. many with cortisol of cancer end by trial Cushing's women with a with belief liver which in animal and help discussing in received proving combined us patients presumed In shown can step in the relacorilant is this has positive Finally, our work. models development findings announced and
more we enough combination At business financial Even trials confident commercial oncology cortisol pandemic activities. two Meanwhile, important development growth our four the our than our later of our this program anti-cancer proprietary weight quarter, conducting difficult improve depressed conditions program in with cash While metabolic first and present in different in our advancing to are NASH results, is fund as will resume generated evaluating a quarter our in agents three gain. types. tumor is antipsychotic induced modulators year.
enroll We in flagship other continued X Cushing's indications. and in patients studies in trials Phase syndrome our are planned further relacorilant to of
ALS We will patients year. with to CORTXXXXXX this later treat advance
continue toward breadth New the is a our early program Cortisol flag. therapeutic stage reflects modulation compounds, our scientific of The hypothesis. to advance of power modality. fundamental the powerful
proven patients proves its that body other patients disorders. the Today that we work evidence added We have Cushing's to with of syndrome. your stop with for answer in serious questions. to I'll here
